Overview

Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:
0

Participant gender:
All

Summary

This prospective, multicenter, non-interventional study will enroll participants from routine clinical practice in Germany who are receiving tocilizumab for RA. The objective of the study is systematic collection of data on use of tocilizumab in daily routine with special emphasis on treatment decision by the prescriber, compliance with Summary of Product Characteristics (SmPC), and documentation of relevant activity scores and adverse drug reactions (ADRs). The maximum observation period will be 12 months per participant.

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Hoffmann-La Roche

Criteria

Inclusion Criteria:

- Moderate to severe RA

- Tocilizumab indicated in accordance with SmPC and chosen by the treating physician in
advance of the study

Exclusion Criteria:

- None specified